http://orcid.org/0000-0003-4842-8762
References
- Chawla PK, Lokhande RV, Naik PR, et al. Failure to reach therapeutic levels of rifampicin and isoniazid by recommended dosages. Infect Dis (Lond). 2017;49(7):552–555.
- World Health Organization. Guidelines for treatment of tuberculosis. Geneva, Switzerland: World Health Organization; 2010 [cited 2020 Jan 20]. Available from: https://www.who.int/tb/publications/2010/9789241547833/en
- Santos NPC, Callegari-Jacques SM, Ribeiro dos Santos AKC, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis. 2013;17(4):499–504.
- Prasanthi B, Ratna JV, Phani R. Development and validation of RP-HPLC method for simultaneous estimation of rifampicin, isoniazid and pyrazinamide in human plasma. J Anal Chem. 2015;70(8):1015–1022.
- Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol. 2006;62(5):1220–1227.
- Fahimi F, Tabarsi P, Kobarfard F, et al. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013;17(12):1602–1606.
- Erwin ER, Addison AP, John SF, et al. Pharmacokinetics of isoniazid: the good, the bad, and the alternatives. Tuberculosis (Edinb.) 2019;116:S66–S70.
- Alfarisi O, Mave V, Gaikwad S, et al. Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrob Agents Chemother. 2018;62(11) DOI:10.1128/AAC.01383-18.
- Hemanth Kumar AK, Chandrasekaran V, Kannan T, et al. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus. Eur J Clin Pharmacol. 2017;73(1):65–67.
- Mota L, Al-Efraij K, Campbell JR, et al. Therapeutic drug monitoring in antituberculosis treatment: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016; 20(6):819–826.